CUEDC2: An emerging key player in inflammation and tumorigenesis

Protein and Cell

Volumn 2, Issue 9, 2011, Pages 699-703

  Man, Jianghong ^a   Zhang, Xuemin ^a  

^a NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

Author keywords

cell cycle; CUEDC2; inflammation; nuclear factor B; tumorigenesis

Indexed keywords

ANAPHASE PROMOTING COMPLEX; BIOLOGICAL MARKER; CELL CYCLE PROTEIN 20; CUE DOMAIN CONTAINING 2 PROTEIN; CYCLIN DEPENDENT KINASE 1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROGESTERONE RECEPTOR; PROTEASOME; REGULATOR PROTEIN; TAMOXIFEN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANEUPLOIDY; BREAST CANCER; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SECRETION; DISEASE MARKER; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; INFLAMMATION; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SPINDLE CELL; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; UBIQUITINATION;

EID: 80955155442     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-011-1089-z     Document Type: Review

References (43)

1. Aggarwal, B. B., Vijayalekshmi, R. V., and Sung, B. (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15, 425-430.
2. Arpino, G., Wiechmann, L., Osborne, C. K., and Schiff, R. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29, 217-233.
3. Baselga, J., and Norton, L. (2002). Focus on breast cancer. Cancer Cell 1, 319-322.
4. Bollen, M., Peti, W., Ragusa, M. J., and Beullens, M. (2010). The extended PP1 toolkit: designed to create specificity. Trends Biochem Sci 35, 450-458.
5. Chen, G., and Goeddel, D. V. (2002). TNF-R1 signaling: a beautiful pathway. Science 296, 1634-1635.
6. Cui, J., Zhu, L., Xia, X., Wang, H. Y., Legras, X., Hong, J., Ji, J., Shen, P., Zheng, S., Chen, Z. J., et al. (2010). NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 141, 483-496.
7. Donaldson, K. M., Yin, H., Gekakis, N., Supek, F., and Joazeiro, C. A. (2003). Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. Curr Biol 13, 258-262.
8. Gao, Y. F., Li, T., Chang, Y., Wang, Y. B., Zhang, W. N., Li, W. H., He, K., Mu, R., Zhen, C., Man, J. H., et al. (2011). Cdk1-phosphorylated CUEDC2 promotes spindle checkpoint inactivation and chromosomal instability. Nat Cell Biol 13, 924-933.
9. Gown, A. M. (2008). Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21, S8-S15.
10. Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F., and Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296.
11. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
12. Häcker, H., and Karin, M. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE 2006, re13.
13. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
14. Hsu, H., Huang, J., Shu, H. B., Baichwal, V., and Goeddel, D. V. (1996). TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4, 387-396.
15. Huang, Q., Yang, J., Lin, Y., Walker, C., Cheng, J., Liu, Z. G., and Su, B. (2004). Differential regulation of interleukin 1 receptor and Tolllike receptor signaling by MEKK3. Nat Immunol 5, 98-103.
16. Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436.
17. Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-663.
18. Karin, M., and Greten, F. R. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5, 749-759.
19. Li, H. Y., Liu, H., Wang, C. H., Zhang, J. Y., Man, J. H., Gao, Y. F., Zhang, P. J., Li, W. H., Zhao, J., Pan, X., et al. (2008). Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat Immunol 9, 533-541.
20. Maeda, S., Kamata, H., Luo, J. L., Leffert, H., and Karin, M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990.
21. Maniatis, T. (1999). A ubiquitin ligase complex essential for the NFkappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 13, 505-510.
22. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancerrelated inflammation. Nature 454, 436-444.
23. Minton, K. (2008). Stopping before the damage is done. Nat Rev Immunol 8, 372-379.
24. Morgan, D. O. (1999). Regulation of the APC and the exit from mitosis. Nat Cell Biol 1, E47-E53.
25. Musgrove, E. A., and Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631-643.
26. Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., and Okumura, K. (1998). Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaBinducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A 95, 3537-3542.
27. Nigg, E. A. (2001). Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2, 21-32.
28. Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., and Perrone, F., and the NCI-Naple Breast Cancer Group. (2005). Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12, 721-747.
29. Page, A. M., and Hieter, P. (1999). The anaphase-promoting complex: new subunits and regulators. Annu Rev Biochem 68, 583-609.
30. Pan, X., Zhou, T., Tai, Y. H., Wang, C., Zhao, J., Cao, Y., Chen, Y., Zhang, P. J., Yu, M., Zhen, C., et al. (2011). Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med 17, 708-714.
31. Peters, J. M. (2006). The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7, 644-656.
32. Pines, J., and Rieder, C. L. (2001). Re-staging mitosis: a contemporary view of mitotic progression. Nat Cell Biol 3, E3-E6.
33. Renner, F., and Schmitz, M. L. (2009). Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem Sci 34, 128-135.
34. Schvartzman, J. M., Sotillo, R., and Benezra, R. (2010). Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10, 102-115.
35. Shih, S. C., Prag, G., Francis, S. A., Sutanto, M. A., Hurley, J. H., and Hicke, L. (2003). A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J 22, 1273-1281.
36. Sullivan, M., and Morgan, D. O. (2007). Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8, 894-903.
37. Visintin, R., Prinz, S., and Amon, A. (1997). CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science 278, 460-463.
38. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003). Tumor necrosis factor signaling. Cell Death Differ 10, 45-65.
39. Weaver, B. A., and Cleveland, D. W. (2008). The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell 14, 431-433.
40. Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15, 1016-1022.
41. Yamashita, H. (2008). Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13, 380-383.
42. Yang, J., Lin, Y., Guo, Z., Cheng, J., Huang, J., Deng, L., Liao, W., Chen, Z., Liu, Z., and Su, B. (2001). The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2, 620-624.
43. Zhang, P. J., Zhao, J., Li, H. Y., Man, J. H., He, K., Zhou, T., Pan, X., Li, A. L., Gong, W. L., Jin, B. F., et al. (2007). CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitinproteasome. EMBO J 26, 1831-1842.